Among the various immunological and non-immunological tumor-promoting activities of
myeloid-derived suppressor cells (MDSCs), their immunosuppressive capacity remains a …

Although cancer chemotherapy has historically been considered immune suppressive, it is
now accepted that certain chemotherapies can augment tumor immunity. The recent …

Immunotherapy has shown great promise in the fight against cancer, as evidenced by the
clinical efficacy of chimeric antigen receptor T cells in hematologic malignancies and …

Dendritic cells (DCs) are the most potent antigen-presenting cells, and tumor antigen-loaded
DCs (DC-vaccines) can activate tumor-specific cytotoxic T lymphocytes (CTLs) in lymphatic …

BACKGROUND. Recent genomic and bioinformatic technological advances have made it
possible to dissect the immune response to personalized neoantigens encoded by tumor …

Cancer immunotherapy, including immune checkpoint blockade and adoptive CAR T‐cell
therapy, has clearly established itself as an important modality to treat melanoma and other …

Tumor-induced expansion of myeloid-derived suppressor cells (MDSCs) is known to impair
the efficacy of cancer immunotherapy. Among pharmacological approaches for MDSC …

Elevated levels of myeloid-derived suppressor cells (MDSCs) induced by tumor-derived
factors are associated with inhibition of immune responses in patients with gastrointestinal …

Pancreatic ductal adenocarcinoma (PDAC) is often refractory to treatment with gemcitabine
(GEM) and immune checkpoint inhibitors including anti-programmed cell death ligand 1 (PD …

Dendritic cells (DCs) are antigen-presenting cells (APCs) that are essential for the activation
of immune responses. In various malignancies, these immunostimulatory properties are …